Profil
Wolfgang Barth is currently working as a Development Director at AC Immune SA since 2013.
Previously, he held positions as a Director-Project Management at Bayer Corp., a Principal at Bayer AG, and a Member-Supervisory Board at Hypothekenbank Frankfurt AG.
From 2004 to 2008, he served as a Vice President-Development at Avontec GmbH.
He also worked as the Head-Development at TRIN Pharma GmbH.
Dr. Barth holds a doctorate degree from Philipps University of Marburg.
Anciens postes connus de Wolfgang Barth
| Sociétés | Poste | Fin |
|---|---|---|
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Corporate Officer/Principal | 18/06/2008 |
Hypothekenbank Frankfurt AG
 Hypothekenbank Frankfurt AG Financial ConglomeratesFinance Hypothekenbank Frankfurt AG provides real estate and public sector finance. The company offers commercial real estate, public sector finance and real estate investment banking in Europe and the US. It gives residential loans in Germany. Hypothekenbank Frankfurt was founded in 2002 and is headquartered in Eschborn, Germany. | Directeur/Membre du Conseil | 13/07/2006 |
TRIN Pharma GmbH
 TRIN Pharma GmbH Medical/Nursing ServicesHealth Services TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization. | Corporate Officer/Principal | - |
| AC IMMUNE SA | Corporate Officer/Principal | - |
| BAYER AG | Corporate Officer/Principal | - |
Formation de Wolfgang Barth
| Philipps University of Marburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BAYER AG | Health Technology |
| AC IMMUNE SA | Health Technology |
| Entreprise privées | 4 |
|---|---|
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
Hypothekenbank Frankfurt AG
Hypothekenbank Frankfurt AG Financial ConglomeratesFinance Hypothekenbank Frankfurt AG provides real estate and public sector finance. The company offers commercial real estate, public sector finance and real estate investment banking in Europe and the US. It gives residential loans in Germany. Hypothekenbank Frankfurt was founded in 2002 and is headquartered in Eschborn, Germany. | Finance |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
TRIN Pharma GmbH
TRIN Pharma GmbH Medical/Nursing ServicesHealth Services TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization. | Health Services |
